• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Brand Quest
• The New Manager
• BL Club
• Smartbuy
• Books
• Gallery

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth
• Events 2007

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

Mumbai, July 10 Sun Pharmaceutical has entered into agreements with Forest to settle legal proceedings on Lexapro (escitalopram oxalate) tablets, used as an anti-depressant.

The deal has been formalised between Sun Pharma and its subsidiaries along with Caraco Pharmaceutical (also Sun’s US-based subsidiary), and Forest Laboratories, Forest Laboratories Holdings and H. Lundbeck. These agreements will be subject to review by the US Federal Trade Commission, a note from Sun Pharma said.

As part of the pact, Sun Pharma will license to Lundbeck on a global basis certain patent applications related to the synthesis of escitalopram and citalopram for an upfront payment and if the technology is used, royalties on sales, Sun Pharma said.

Forest will provide licences to Caraco for any patents related to Lexapro.

Also, Caraco will also be able to market the generic version when any third party generic-maker (other than an authorised player or a first-filer) is allowed by the US regulatory authority to sell in the market.

Caraco will take over the commercialisation and sale of several products from Forest’s Inwood business.

Caraco will also pay Forest an undisclosed advance against royalties and royalties on net sales of these products, the note said. Forest will reimburse Caraco for a portion of their costs related to this litigation.

Copyright © 2009, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line